OverviewChartNewsTraderScreen

UBS Knock-Out IDP/  DE000UM2W6Y6  /

Frankfurt Zert./UBS
7/31/2024  3:56:05 PM Chg.+0.020 Bid4:13:17 PM Ask4:13:17 PM Underlying Strike price Expiration date Option type
0.480EUR +4.35% 0.460
Bid Size: 50,000		 0.470
Ask Size: 50,000		 BIOGEN INC. DL -,000... 164.1606 - 12/31/2078 Call
GlobeNewswire 6/28 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
GlobeNewswire 6/24 TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
GlobeNewswire 6/10 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application f...
GlobeNewswire 6/3 Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of ...
GlobeNewswire 5/30 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...
GlobeNewswire 5/22 Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Im...
GlobeNewswire 5/21 Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
GlobeNewswire 5/16 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire 5/15 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire 5/2 Biogen Reports Progress on Corporate Responsibility Priorities
GlobeNewswire 4/25 Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
TeleTrader 4/24 Biogen posts Q1 revenue of $2.3 billion
GlobeNewswire 4/23 Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire 4/2 ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
GlobeNewswire 3/6 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire 3/4 Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire 2/23 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
TeleTrader 2/13 Biogen's Q4 revenue falls 6% to $2.4 billion
GlobeNewswire 2/12 Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...
TeleTrader 2/12 Earnings preview: Robinhood, Coinbase and more
GlobeNewswire 2/8 Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire 1/4 Stran & Company Appoints Ian Thomas Wall as Chief Information Officer
GlobeNewswire 12/19/2023 Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire 12/15/2023 CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...
GlobeNewswire 12/14/2023 ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is...